Phase 2

Breast Cancer Clinical Trial

Recruiting
Recruiting
Recruiting
Recruiting
Estimated trial completion date
Nov 1, 2031

Join this Clinical trial

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

PREDICT-RD

This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional neoadjuvant chemo-immunotherapy followed by surgery.

‍

Patients are eligible if they are/have:

Written informed consent was obtained to participate in the study, and HIPAA authorization for the release of personal health information.

  • Participant is willing and able to comply with study procedures based on the judgment of the investigator.
  • Age ≥ 18 years at the time of consent.
  • Histological confirmation of TNBC defined by ER/PR <10%, HER2 0-1+ by IHC or 2+ by IHC and fluorescence in situ hybridization (FISH) negative.
  • Stage II/III TNBC treated with neoadjuvant systemic therapy AND have residual disease defined as RCB II/III at time of surgery.
  • Baseline staging scans at the discretion of the treating physician and demonstrate no evidence of metastatic disease.
  • The participant must have archival diagnostic tissue and/or surgical resection tissue Available.
  • Participants are willing and able to comply with study procedures based on the judgment of the investigator.

Join this Clinical trial

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Join the PREDICT-RD Clinical Trial

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.